Rebranding efforts include a new logo, overall brand presence, and corporate design.

Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports.

HC Wainwright reissued their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report report published on Thursday,Benzinga reports.

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $25.00 expecting ZVRA to rise to within 12 ...

During the last three months, 5 analysts shared their evaluations of Zevra Therapeutics (NASDAQ:ZVRA), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...

Neil Mcfarlane; President, Chief Executive Officer, Director; Zevra Therapeutics Inc Joshua Schafer; Chief Commercial Officer and Executive Vice President, Business Development; Zevra Therapeutics ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.67 EPS, expectations were $-0.39.

Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded, and will be ...

Citizens JMP raised the firm’s price target on Zevra Therapeutics (ZVRA) to $18 from $17 and keeps an Outperform rating on the shares. Zevra reported Q4 revenue that was significantly ahead of ...